Literature DB >> 10982071

Sero-epidemiology of rubella in the urban population of Addis Ababa, Ethiopia.

F T Cutts1, A Abebe, T Messele, A Dejene, F Enquselassie, W Nigatu, D J Nokes.   

Abstract

We conducted a community-based cluster sample survey of rubella sero-epidemiology in Addis Ababa, Ethiopia in 1994. Among 4666 individuals for whom complete data were available, rubella antibody prevalence was 91% (95% confidence interval: 90, 92). On multivariable analysis, seroprevalence was lower among individuals who were resident in Addis Ababa for 1 year or less. Approx. 50% seroprevalence was attained by age 4 years, and the estimated average age at infection was 5.2 years. The highest age-specific force of infection was estimated to occur in 5- to 9-year-olds. The early age at infection corresponded with a low estimated incidence of congenital rubella syndrome (CRS) of 0.3 per 1000 live births, equivalent to nine cases of CRS in 1994. The predicted critical level of immunity for elimination of rubella via vaccination was 85-91%, requiring 89-96% coverage with a vaccine of 95% effectiveness. Unless very high coverage of rubella vaccine could be guaranteed, the introduction of childhood vaccination could increase the incidence of CRS in Addis Ababa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982071      PMCID: PMC2810933          DOI: 10.1017/s0950268899003532

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  13 in total

1.  Measles and Rubella Seroprevalence Among HIV-infected and Uninfected Zambian Youth.

Authors:  Catherine G Sutcliffe; Kelly Searle; Hellen K Matakala; Michelle P Greenman; Kaitlin Rainwater-Lovett; Philip E Thuma; William J Moss
Journal:  Pediatr Infect Dis J       Date:  2017-03       Impact factor: 2.129

2.  Seroprevalence of rubella in school girls and pregnant women.

Authors:  Gulbin Bingol Karakoc; Derya Ufuk Altintas; Banu Kilinc; Aysun Karabay; Neslihan Onenli Mungan; Mustafa Yilmaz; Nurdan Evliyaoglu
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

3.  Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].

Authors:  Ikechukwu Adigweme; Edem Akpalu; Mohammed Yisa; Simon Donkor; Lamin B Jarju; Baba Danso; Anthony Mendy; David Jeffries; Abdoulie Njie; Andrew Bruce; Michael Royals; James L Goodson; Mark R Prausnitz; Devin McAllister; Paul A Rota; Sebastien Henry; Ed Clarke
Journal:  Trials       Date:  2022-09-14       Impact factor: 2.728

Review 4.  Rubella.

Authors:  Nathaniel Lambert; Peter Strebel; Walter Orenstein; Joseph Icenogle; Gregory A Poland
Journal:  Lancet       Date:  2015-01-08       Impact factor: 79.321

5.  Impact of birth rate, seasonality and transmission rate on minimum levels of coverage needed for rubella vaccination.

Authors:  C J E Metcalf; J Lessler; P Klepac; F Cutts; B T Grenfell
Journal:  Epidemiol Infect       Date:  2012-02-16       Impact factor: 4.434

Review 6.  Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review.

Authors:  Emilia Vynnycky; Elisabeth J Adams; Felicity T Cutts; Susan E Reef; Ann Marie Navar; Emily Simons; Lay-Myint Yoshida; David W J Brown; Charlotte Jackson; Peter M Strebel; Alya J Dabbagh
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

7.  Implications of spatially heterogeneous vaccination coverage for the risk of congenital rubella syndrome in South Africa.

Authors:  C J E Metcalf; C Cohen; J Lessler; J M McAnerney; G M Ntshoe; A Puren; P Klepac; A Tatem; B T Grenfell; O N Bjørnstad
Journal:  J R Soc Interface       Date:  2013-01-06       Impact factor: 4.118

8.  Balancing evidence and uncertainty when considering rubella vaccine introduction.

Authors:  Justin Lessler; C Jessica E Metcalf
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

9.  Introduction of rubella-containing-vaccine to Madagascar: implications for roll-out and local elimination.

Authors:  Amy Wesolowski; Keitly Mensah; Cara E Brook; Miora Andrianjafimasy; Amy Winter; Caroline O Buckee; Richter Razafindratsimandresy; Andrew J Tatem; Jean-Michel Heraud; C Jessica E Metcalf
Journal:  J R Soc Interface       Date:  2016-04       Impact factor: 4.118

10.  Rubella vaccination in India: identifying broad consequences of vaccine introduction and key knowledge gaps.

Authors:  A K Winter; S Pramanik; J Lessler; M Ferrari; B T Grenfell; C J E Metcalf
Journal:  Epidemiol Infect       Date:  2017-12-04       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.